Biologics Exclusivity: GPhA Making Last Stand Against TPP
This article was originally published in PharmAsia News
Executive Summary
The U.S. Generic Pharmaceutical Association and other groups are opposing the Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
You may also be interested in...
Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has focused on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use that as a template for future free trade agreements.
Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.